scholarly journals The Tetraodon nigroviridis reference transcriptome: developmental transition, length retention and microsynteny of long non-coding RNAs in a compact vertebrate genome

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Swaraj Basu ◽  
Yavor Hadzhiev ◽  
Giuseppe Petrosino ◽  
Chirag Nepal ◽  
Jochen Gehrig ◽  
...  
Keyword(s):  
Vertebrate Genome ◽  
Reference Transcriptome ◽  
Developmental Transition ◽  
Tetraodon Nigroviridis ◽  
Transition Length ◽  
Non Coding Rnas

Long Non-Coding RNAs Are Commonly Deregulated in Hodgkin Lymphoma

2014 ◽  
Vol 226 (02) ◽  
Author(s):  
A van den Berg ◽  
M Tayari ◽  
G Kortman ◽  
J Sietzema ◽  
D de Jong ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Non Coding Rnas

MicroRNAs and their role in hematological malignant diseases

2012 ◽  
Vol 153 (52) ◽  
pp. 2051-2059 ◽  
Author(s):  
Zsuzsanna Gaál ◽  
Éva Oláh
Keyword(s):  
Target Genes ◽  
Lymphoblastic Leukemia ◽  
Cancer Tissue ◽  
Altered Expression ◽  
Diagnosis And Prognosis ◽  
Oncologic Patients ◽  
Different Types ◽  
Non Coding Rnas ◽  
Success Of Treatment ◽  
Posttranscriptional Level

MicroRNAs are a class of small non-coding RNAs regulating gene expression at posttranscriptional level. Their target genes include numerous regulators of cell cycle, cell proliferation as well as apoptosis. Therefore, they are implicated in the initiation and progression of cancer, tissue invasion and metastasis formation as well. MicroRNA profiles supply much information about both the origin and the differentiation state of tumours. MicroRNAs also have a key role during haemopoiesis. An altered expression level of those have often been observed in different types of leukemia. There are successful attempts to apply microRNAs in the diagnosis and prognosis of acute lymphoblastic leukemia and acute myeloid leukemia. Measurement of the expression levels may help to predict the success of treatment with different kinds of chemotherapeutic drugs. MicroRNAs are also regarded as promising therapeutic targets, and can contribute to a more personalized therapeutic approach in haemato-oncologic patients. Orv. Hetil., 2012, 153, 2051–2059.

Sign in / Sign up

Export Citation Format

Share Document